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Abstract
In polyglutamine (polyQ) diseases including Huntington’s disease (HD), mutant proteins containing expanded polyQ stretch
form aggregates in neurons. Genetic or RNAi screenings in yeast, C. elegans or Drosophila have identified multiple genes
modifying polyQ aggregation, a few of which are confirmed effective in mammals. However, the overall molecular
mechanism underlying polyQ protein aggregation in mammalian cells still remains obscure. We here perform RNAi
screening in mouse neuro2a cells to identify mammalian modifiers for aggregation of mutant huntingtin, a causative
protein of HD. By systematic cell transfection and automated cell image analysis, we screen ,12000 shRNA clones and
identify 111 shRNAs that either suppress or enhance mutant huntingtin aggregation, without altering its gene expression.
Classification of the shRNA-targets suggests that genes with various cellular functions such as gene transcription and
protein phosphorylation are involved in modifying the aggregation. Subsequent analysis suggests that, in addition to the
aggregation-modifiers sensitive to proteasome inhibition, some of them, such as a transcription factor Tcf20, and kinases
Csnk1d and Pik3c2a, are insensitive to it. As for Tcf20, which contains polyQ stretches at N-terminus, its binding to mutant
huntingtin aggregates is observed in neuro2a cells and in HD model mouse neurons. Notably, except Pik3c2a, the rest of
the modifiers identified here are novel. Thus, our first large-scale RNAi screening in mammalian system identifies previously
undescribed genetic players that regulate mutant huntingtin aggregation by several, possibly mammalian-specific
mechanisms.
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Introduction
Polyglutamine (polyQ) diseases are adult-onset hereditary
neurodegenerative disorders. These include Huntington’s disease
(HD), spinocerebellar ataxias (SCA1, 2, 3, 6, 7, 17), dentatorubral-
pallidoluysian atrophy (DRPLA) and spinobulbar muscular
atrophy (SBMA). The polyQ diseases are caused by expansion
of CAG repeats in certain causative genes. The mutant proteins
containing expanded polyQ stretch are misfolded and aggregated,
leading to formation of nuclear inclusions in neurons [1,2].
The polyQ protein aggregation accompanies sequestration of
several cellular components such as transcription factors [3–7] and
RNA binding proteins [8,9], leading to dysregulation of gene
expression during neurodegeneration [10–12]. In addition, polyQ-
mediated cell toxicity is reported to be reduced through
suppressing polyQ aggregation by chaperones [13–18], chaper-
onin [19–21], QBP1 (polyQ-binding peptide 1) [22,23], or
chemical compounds such as Congo Red [24] or trehalose [25].
Thus, examination of molecular mechanisms underlying polyQ
aggregation is one of the effective strategies for understanding
pathomechanism of and searching therapeutic targets for polyQ
diseases.
In past 10 years, several groups have performed genetic or RNA
interference (RNAi) screening to identify polyQ aggregation-
modifying genes using yeast [26], C. elegans [27–30] or Drosophila
models [31–34]. These screenings have identified genes in various
contexts such as transcription, RNA processing, protein transport
and signal transduction, in addition to protein folding and
degradation. These observations suggest that multiple cellular
pathways are involved in the regulation of polyQ protein
aggregation in non-mammalian systems. Although a few of their
orthologues are shown to modify polyQ protein aggregation in
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e93891mammalian cells [26,34], a large-scale, systematic screen has not
been performed in any mammalian systems and the overall
molecular mechanism underlying polyQ protein aggregation in
mammalian cells remains obscure.
To this end, we perform RNAi screening in mouse neuroblas-
toma cells to attempt to identify novel aggregation-modifiers for
mutant huntingtin (Htt), a causative protein of HD, in mammals.
To the best of our knowledge, this is the first comprehensive
analysis of polyQ aggregation-modifying genes in mammals. We
transduce ,12000 short hairpin RNA (shRNA) clones into
neuro2a cells that inducibly express mutant Htt, and analyze the
aggregation by automated quantitative fluorescence microscopy.
After three screenings, we identify 111 shRNAs that specifically
modify the mutant Htt aggregation in neuro2a cells. Subsequent
analyses suggest that the modifications can be mediated by several
mechanisms, that is, by direct/indirect regulation through
proteasome-dependent/-independent pathways. Importantly, all
of the shRNA targets except of one gene [33] are not found by
previous screenings using other organisms described above. Thus,
our RNAi screening identifies previously undescribed genes
involved in mutant Htt aggregation in mammalian cells.
Results
Identification of shRNAs that modify mutant Nhtt
aggregation in neuro2a cells
To identify modifiers of mutant Htt aggregation in mammalian
cells, we performed shRNA screening using mouse neuro2a cells
that inducibly expressed exon 1 of Htt (Nhtt) containing a 150Q
tagged with an EGFP at its C-terminus (Nhtt150Q-EGFP), under
the control of ponasterone A [35]. shRNA libraries were
purchased from Open Biosystems, in which shRNA clones were
supplied as E. coli glycerol stocks in 96 well plate-formats. We used
total 122 plates for plasmid DNA purification and obtained 11346
shRNA clones with transfection grade DNA. Scheme of experi-
mental procedure is outlined in Figure 1. First, neuro2a cells were
seeded on 96 well plates and transiently transfected with shRNA
clones. Cells were then differentiated by dibutyryl cyclic AMP
(dcAMP) on the same day and selected with puromycin on the
next day. After the selection, they were treated with ponasterone A
to induce Nhtt150Q-EGFP expression. EGFP positive aggregates
will be allowed to form for one day. After fixation and nuclear
staining with DAPI or Hoechst, the number of aggregates-
containing cells and total number of cells were automatically
quantified by Cellomics ArrayScan HCS Reader, a cell image
analyzer equipped with fluorescence microscopy.
The screening strategy is summarized in Figure 2. In the first
screening, we screened 11346 shRNA clones based on the z score
(mean z score is ,21.5 or .1.5) and finally obtained 602 shRNAs
that were able to modify Nht150Q-EGFP aggregation in neuro2a
cells (Figure 3A). To exclude the shRNAs that modify the
aggregation purely acting on Nhtt expression itself, we performed
a second screen, in which we used neuro2a cells expressing non-
aggregating Nhtt16Q-EGFP [35]. After transfection and induction
of Nhtt16Q-EGFP expression as above, EGFP intensities in the
cells were quantified by ArrayScan reader. Through this analysis,
we noticed that the shRNAs that induced Nhtt16Q-EGFP
expression were relatively enriched in the aggregation-enhancing
shRNAs (Figure 3B), suggesting that their enhancing effect was just
caused by inducing Nhtt expression. After the second screen, 270
shRNAs were remained as candidates as they did not show
significant alteration in Nhtt16Q-EGFP expression (Figure 3B). To
obtain shRNAs that reproducibly modifying aggregation, we again
used Nhtt150Q-EGFP cells for the third screening. Finally, we
obtained 111 shRNAs that specifically and reproducibly modified
Nhtt150Q-EGFP aggregation in neuro2a cells (Figure 3C).
Validation, classification and proteasome-dependency of
the aggregation-modification by the identified shRNAs
Among the final 111 shRNAs, 63 suppressed and 48 enhanced
the aggregation of mutant Nhtt (Table 1, 2) (complete screening
data for 111 candidates are described in Data S1). Figure 3D
shows representative cell images of the aggregation-modification
by the shRNAs; Atf3 or Ppt2 shRNAs reduced Nhtt-150QEGFP
aggregates compared with non-silencing control whereas Cish or
Gnai2 shRNAs increased them. To validate the gene-knockdown
effect by the shRNAs, we designed other RNAi sequences (Inv-1
and -2) by Invitrogen’s BLOCK-iT RNAi Designer for some of
the genes (Data S2), and expressed as miRNA (miR RNAi) using
Figure 1. Experimental procedure of screening of shRNAs that
modify Nhtt150Q-EGFP aggregation in neuro2a cells. Neuro2a
cells inducibly expressing Nhtt150Q-EGFP under ecdysone-responsive
element (EcRE) were seeded on a 96 well culture plate. On the next day,
the cells were transiently transfected with shRNAs prepared from shRNA
library plates. The cells were then differentiated by dcAMP on the same
day and selected with puromycin on the next day, after which they
were treated with ponasterone A to induce Nhtt150Q-EGFP expression.
After 24 hr, the cells were fixed with 4% PFA and incubated with DAPI
or Hoechst for nuclear staining. Fluorescence cell images were
automatically obtained and analyzed by ArrayScan HCS Reader, and
percent of cells with Nhtt150Q-EGFP aggregates among total analyzed
cells was calculated.
doi:10.1371/journal.pone.0093891.g001
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tion-modifying ability in 12 out of 15 genes (80%) by at least one of
the miRNAs (Figure 3E), supporting the validity of our screening
strategy and results.
To examine the molecular mechanism underlying mutant Nhtt
aggregation by these shRNAs, we classified the final 111 shRNA-
target genes using PANTHER Classification System [37]. When
focused on molecular function, they were classified into various
functions such as catalytic, receptor and transcription regulator
activities (Figure 4A). Classification by PANTHER protein class
also suggests the genes with various activities involved in mutant
Nhtt aggregation (Figure 4B). Another Classification method
further suggests the involvement of multiple biological processes in
the aggregation modification (Figure 4C). Although no marked
difference was observed between the target genes of the
aggregation-suppressing and -enhancing shRNAs, transcription
factors such as Atf3 and Tcf20 was more abundant in the
suppressors’ targets (12.7%; 8 out of 63) than the enhancers’
targets (4.1%; 2 out of 48) (Figure 4A, B). In contrast, genes for
membrane trafficking such as Stxbp1 and Snx10 were only found
in the enhancers’ targets (8.3%; 4 out of 48) (Figure 4B). We also
performed Statistical Overrepresentation Test using PANTHER
Classification System, however any of gene ontology (GO) term or
pathway was not significantly enriched (data not shown). These
data suggest that genes with broad molecular and biological
functions modify the mutant Nhtt aggregation whereas some
specific cellular functions such as gene transcription and mem-
brane trafficking may be differentially involved in the modifica-
tion.
Several lines of studies have suggested an involvement of
ubiquitin-proteasome system, a major protein degradation system
in cells, in mutant Htt degradation [34,38–41]. In addition,
another degradation system, autophagy, is also recently shown to
be involved in clearance mutant Htt aggregates [36,42–45]. To
examine whether the aggregation-modification by identified
shRNAs involves these systems, we picked up 10 aggregation-
suppressing shRNAs whose targets have various molecular and
biological functions (Figure 4), and examined their effect in the
presence of MG132 or bafilomycin A1 (Baf A1), inhibitor of
proteasome or autophagy, respectively. We found that MG132 but
not Baf A1 relieved the aggregation-suppressing effect of several
shRNAs, such as those for Atf3, Cradd, Tmem179b and Pdcd4
(Figure 5), suggesting that these genes modify the mutant Nhtt
aggregation through proteasome-dependent mechanism.
Tcf20 binds to mutant Nhtt aggregates in neuro2a cells
and R6/2 mouse brain neurons
In addition to the genes whose shRNAs’ effect was sensitive to
MG132 as described above, we found several genes including Ppt2
and Tcf20 whose shRNAs’ effect was insensitive to it (Figure 5),
suggesting proteasome-independent modification by these genes.
Among them, we focused on Tcf20 because it is relatively Q-rich
(Q composition is 9.7%) among the identified modifiers (mean Q
composition is 4.5961.92%) and notably it contains several polyQ
stretches in the N-terminal region (Figure 6A). Because some of Q-
rich proteins are shown to directly co-aggregate with mutant Htt
[3–6,8,9], it is possible that Tcf20 directly interacts with mutant
Nhtt aggregates.
To examine this possibility, we cloned Tcf20 cDNA into
pcDNA-DEST40 vector with a V5 tag at its C-terminus, and
expressed Tcf20-V5 in neuro2a cells together with Nhtt150Q-
EGFP-NLS (nuclear localization signal). As shown in Figure 6B,
Tcf20-V5 was clearly co-localized with Nhtt150Q-EGFP-NLS
aggregates, whereas it was only diffusely localized in the nucleus in
the cells without the aggregates. Tcf20-V5 was also co-localized
with cytoplasmic Nhtt150Q-EGFP aggregates (Figure 6C). In
contrast, these co-localization was not observed for LacZ or other
potential modifiers without polyQ-stretch such as Rab2b and
Ddr2 (Q compositions are 5.6% and 4.0%, respectively)
(Figure 6C; Ddr2, data not shown). We further found that Tcf20
N-terminal constructs (1,400 and 1,500) containing polyQ
stretches preferentially co-localized with Nhtt150Q-EGFP aggre-
gates (Figure 6C). In addition, these were insolubilized with
Nhtt150Q-EGFP but not with Nhtt16Q-EGFP (Figure 6D),
similar to a known aggregates-interacting protein, NF-YA [5].
Interestingly, overexpression of either N-terminal (1,400 and
1,500) or full-length of Tcf20 suppressed Nhtt150Q-EGFP
aggregation (Figure 6E), suggesting that the Tcf20 interaction
through its N-terminus suppresses mutant Nhtt aggregation when
overexpressed. Finally, an antibody against Tcf20 stained puncta
positive for Htt and Ub in cortical neurons of HD model mouse
(Figure 7A, B), suggesting in vivo incorporation of Tcf20 into
Figure 2. Summary of the shRNA screening. Total 11346 shRNA
clones were subjected to the first screening using Nhtt150Q-EGFP cells.
The screening was performed in duplicate (partly in triplicate), and
shRNAs altering Nhtt150Q-EGFP aggregation at ,21.5 or .1.5 of z-
score were selected as positive candidates. Obtained 602 clones were
then subjected to the second screening using Nhtt16Q-EGFP cells to
exclude the shRNAs modifying the aggregation by altering Nhtt
expression itself. shRNAs altering EGFP intensity by 15% compared
with the control were removed. Remaining 270 candidates were
subjected to the third screening using Nhtt150Q-EGFP cells for
confirmation (triplicate). We performed statistical analysis (t-test) in
the third screening and shRNAs with P,0.1 were included as
candidates. Finally, 111 shRNAs were obtained, among which 63
shRNAs suppressed and 48 shRNAs enhanced the Nhtt150Q-EGFP
aggregation.
doi:10.1371/journal.pone.0093891.g002
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that the Tcf20 specifically interacts with mutant Nhtt aggregates
through its N-terminus containing polyQ stretches to be incorpo-
rated into the inclusion. Because both knockdown and overex-
pression showed suppressive effect on mutant Nhtt aggregation,
moderate expression of Tcf20 might be appropriate for efficient
aggregation. Alternatively, its direct interaction and transcriptional
activity could be differentially involved in the regulation of mutant
Nhtt aggregation.
Figure 3. Identification and validation of the shRNAs modifying Nhtt150Q-EGFP aggregation in neuro2a cells. (A) Summarized data of
the first screening using Nhtt150Q-EGFP cells. Mean z-score of 11346 shRNA clones were plotted. shRNAs showing the z-score outside the range of
61.5 were picked up as positive candidates (indicated as blue plots). (B) Summarized data of the second screening using Nhtt16Q-EGFP cells. The
data (relative EGFP intensity; x-axis) were plotted against the first screening data (z-score; y-axis) for 602 shRNA clones. The shRNAs showing the EGFP
intensity within 15% to the control were picked up as positive candidates (indicated as blue plots). (C) Data of the second and third screening for final
111 shRNA candidates. 63 shRNAs suppressed and 48 shRNAs enhanced the Nhtt150Q-EGFP aggregation without distinct alteration of Nhtt16Q-EGFP
expression. (D) Example cell images. Two shRNAs targeting Atf3 or Ppt2 reduced the cells with Nhtt150Q-EGFP aggregates compared with non-
silencing control whereas two shRNAs targeting Cish or Gnaj2 increased them. Bar is 0.2 mm. (E) Validation of the effect of Open Biosystems (OBS)
shRNA by two miRNAs (Inv-1 and -2) binding to different sequences of the genes (Data S2). The S, N and E mean suppression, no-effect and
enhancement for the Nhtt150Q-EGFP aggregation, respectively. In case of Pik3c2a, two different shRNAs were obtained. Note that the shRNA’s effect
was reproduced by at least one miRNA in 12 genes (80% of analyzed genes).
doi:10.1371/journal.pone.0093891.g003
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shRNA 1st (150Q) 2nd (16Q) 3rd (150Q)
No Clone ID Gene z-score Ratio Ratio (+ SD) Gene Description
1 SM2173 d5 1810032O08Rik 21.79 1.03 0.447 (+0.084) RIKEN cDNA 1810032O08 gene
2 SM2177 c4 4933425L06Rik 22.17 1.02 0.447 (+0.160) RIKEN cDNA 4933425L06 gene
3 SM2179 b7 Abat 21.65 0.99 0.493 (+0.086) 4-aminobutyrate aminotransferase
4 SM2574 c8 Aktip 21.60 1.03 0.787 (+0.090) thymoma viral proto-oncogene 1 interacting protein
5 SM2181 c7 Atf3 21.51 1.06 0.499 (+0.093) activating transcription factor 3
6 SM2172 b5 Birc6 22.29 1.07 0.533 (+0.098) baculoviral IAP repeat-containing 6
7 SM2173 f4 Casp3 21.52 1.02 0.563 (+0.237) caspase 3
8 SM2174 e3 Cd24a 22.45 1.03 0.339 (+0.066) CD24a antigen
9 SM2176 a9 Cradd 22.27 0.93 0.241 (+0.028) death domain-containing protein, RAIDD
10 SM2186 h9 Csnk1d 22.22 1.03 0.771 (+0.060) casein kinase 1, delta
11 SM2185 h3 Ddr2 21.52 1.09 0.699 (+0.069) discoidin domain receptor family, member 2
12 SM2168 c8 Ddx6 21.75 1.10 0.467 (+0.038) DEAD (Asp-Glu-Ala-Asp) box polypeptide 6
13 SM2579 f9 Efhb 22.60 1.05 0.793 (+0.122) EF hand domain family, member B
14 SM2558 e11 Enah 21.55 0.96 0.787 (+0.148) enabled homolog (Drosophila)
15 SM2588 a1 Fbxw8 21.57 1.03 0.564 (+0.056) F-box and WD-40 domain protein 8
16 SM2561 e3 Fcgr3 21.90 1.02 0.781 (+0.024) Fc receptor, IgG, low affinity III
17 SM2176 h8 Fgd1 21.92 1.06 0.719 (+0.200) FYVE, RhoGEF and PH domain containing 1
18 SM2560 h6 Fkbp9 22.34 1.01 0.736 (+0.117) FK506 binding protein 9
19 SM2179 b5 Fsd1l 21.62 1.04 0.548 (+0.199) FSD1-like
20 SM2179 e8 Gaa 22.25 0.99 0.664 (+0.095) glucosidase, alpha, acid
21 SM2560 e6 Gjb2 21.77 0.89 0.743 (+0.036) gap junction protein, beta 2
22 SM2177 e1 Gpr37 22.79 1.05 0.680 (+0.141) G protein-coupled receptor 37
23 SM2588 f3 Grhpr 22.14 1.07 0.654 (+0.129) glyoxylate reductase/hydroxypyruvate reductase
24 SM2174 g6 Hoxd3 21.96 0.92 0.527 (+0.167) homeobox D3
25 SM2175 c6 Jagn1 21.68 1.06 0.473 (+0.381) jagunal homolog 1 (Drosophila)
26 SM2591 e6 Klhl7 21.66 1.06 0.635 (+0.120) kelch-like 7
27 SM2134 h10 LOC195242 21.92 1.10 0.650 (+0.099)
28 SM2112 g12 LOC195373 21.59 0.98 0.763 (+0.150)
29 SM2185 a7 Lrguk 21.79 0.95 0.577 (+0.211) leucine-rich repeats and GUK containing
30 SM2587 b3 Mab21l3 21.67 1.03 0.702 (+0.115) mab-21-like 3 (C. elegans)
31 SM2169 g11 Nap1l4 21.57 0.92 0.455 (+0.072) nucleosome assembly protein 1-like 4
32 SM2146 b6 Nlrp10 21.54 1.02 0.641 (+0.058) NLR family, pyrin domain containing 10
33 SM2575 b10 Notch4 22.02 1.00 0.745 (+0.048) notch 4
34 SM2176 f1 Olfr1339 21.99 1.01 0.676 (+0.118) olfactory receptor 1339
35 SM2008 a5 Olfr1451 21.94 1.01 0.746 (+0.160) olfactory receptor 1451
36 SM2174 c1 Olfr339 22.96 0.92 0.526 (+0.062) olfactory receptor 339
37 SM2142 b5 Olfr530 21.89 0.99 0.808 (+0.042) olfactory receptor 530
38 SM2588 f4 Olfr668 22.65 1.00 0.623 (+0.049) olfactory receptor 668
39 SM2562 d2 P2ry1 21.94 0.97 0.764 (+0.136) purinergic receptor P2Y, G-protein coupled 1
40 SM2176 d1 Pdcd4 22.32 0.97 0.512 (+0.123) programmed cell death 4
41 SM2575 a6 Pf4 22.46 0.93 0.780 (+0.041) platelet factor 4
42 SM2183 c12 Pik3c2a 22.08 0.96 0.548 (+0.057) PI 3-kinase, C2 domain containing, alpha
43 SM2185 g9 Pik3c2a 21.99 1.01 0.637 (+0.043) PI 3-kinase, C2 domain containing, alpha
44 SM2134 a11 Pkd1l3 21.53 1.03 0.606 (+0.198) polycystic kidney disease 1 like 3
45 SM2177 e5 Plec 21.82 1.15 0.657 (+0.134) plectin
46 SM2148 a11 Ppfia1 21.58 0.95 0.775 (+0.107) PTPRF, interacting protein (liprin), alpha 1
47 SM2567 f1 Ppt2 22.15 1.06 0.605 (+0.093) palmitoyl-protein thioesterase 2
48 SM2149 a9 Ptprn2 22.03 1.02 0.434 (+0.103) protein tyrosine phosphatase, receptor type, N2
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EGFP aggregates purified from neuro2a cells and identified
several aggregate-interacting proteins such as ubiquilin-1,-2, FUS/
TLS and NF-YA/-YC [5,8,46]. By re-checking the data, we
noticed that Tcf20 was contained in the mass spectrometry data.
In addition, we found other modifiers, Hdac5 and Arhgap24, in
the data, suggesting they are also the proteins incorporated into
the aggregates. Analysis of their amino acid sequences revealed
that Hdac5 but not Arhgap24 is relatively Q-rich (Q compositions
are 8.9% and 4.8%, respectively). We also analyzed the Q
composition of rest of the modifiers, however protein significantly
in Q-rich like Tcf20 or Hdac5 was not found (data not shown).
Taken together, these data suggest that Tcf20 and potentially
Hdac5 are the proteins directly interacting with mutant Nhtt
aggregates among the identified aggregation-modifiers.
Suppression of mutant Nhtt aggregation by knocking
down of Csnk1d and Pik3c2a
To identify other molecular mechanisms regulating mutant
Nhtt aggregation, we focused on kinases, key regulators of
intracellular signal transduction. Our screening identified several
kinases as potential modifiers for mutant Nhtt aggregation
(Table 1, 2). These include Csnk1d, Pik3c2a and Lrguk, whose
shRNAs suppressed the aggregation, and Cmpk1, Map3k1 and
Pip5k1b, whose shRNAs enhanced it. The aggregation-modifying
effect of these shRNAs can be reproduced when we used our own
miRNAs that bind to same region as shRNA (OBS miRNA;
Figure 8A), or different region (Inv-1 or -2 miRNA; Figure 1E, 8B)
supporting the validity of gene knockdown effect of these kinases
on the aggregation-modification. We then focused on two kinases,
Csnk1d and Pik3c2a, whose knockdown suppressed Nhtt150Q-
EGFP aggregation, and confirmed significant and specific
reduction of gene expressions by their miRNAs (Figure 8C). We
further examined the dependency of their knockdown effect on
proteasome or autophagic activity, and found that their miRNAs
were still effective even in the presence MG132 or Baf A1
(Figure 8D). Taken together, these data suggest that Csnk1d and
Pik3c2a are involved in the modification of mutant Nhtt
aggregation through proteasome- and autophagy-independent
mechanisms.
Knockdown of aggregation-modifiers did not suppress
mutant Nhtt-induced cell toxicity
Finally, we examined the effect of knockdown of Tcf20, Csnk1d
or Pik3c2a on cell toxicity induced by mutant Nhtt. For this
purpose, we first synthesized following siRNA oligos based on the
miRNA sequences used above; two for Tcf20 (OBS and Inv-1) and
one for Csnk1d (Inv-1) or Pik3c2a (Inv-1). We first confirmed that
transduction of these siRNA induced significant and specific
reduction of their target genes compared with that of non-
targeting control (NT) in neuro2a cells (Figure 9A). We then
transiently overexpressed Nhtt16Q-EGFP or Nhtt150Q-EGFP in
siRNA-transduced cells. After two days, the cells were incubated
with pyridinium iodide (PI) to detect dead cells, and percent of PI-
positive cells per GFP-positive, Nhtt expressing cells was calculated
by ArrayScan. As shown in Figure 9B, overexpression of
Nhtt150Q-EGFP induced ,3-fold increase in PI-positive cells
compared with that of Nhtt16Q-EGFP, suggesting the induction
of cell toxicity by mutant Nhtt in neuro2a cells. Notably,
knockdown of Tcf20, Csnk1d or Pik3c2a did not suppress the
toxicity rather enhanced it, although their knockdown seemed to
be also effective, but to a lesser extent, in Nhtt16Q-EGFP-
expressing cells (Figure 9B). Altogether, these data suggest that
downregulation of these modifiers dose not suppress mutant Nhtt
toxicity in neuro2a cells.
Discussion
In this paper, we first performed large-scale shRNA screening of
modifiers for mutant Htt aggregation in mammalian cells. By
Table 1. Cont.
shRNA 1st (150Q) 2nd (16Q) 3rd (150Q)
No Clone ID Gene z-score Ratio Ratio (+ SD) Gene Description
49 SM2593 c6 Rab2b 22.36 0.97 0.754 (+0.076) RAB2B, member RAS oncogene family
50 SM2567 a8 Racgap1 22.34 0.93 0.789 (+0.079) Rac GTPase-activating protein 1
51 SM2008 h8 Rfc1 21.65 1.09 0.614 (+0.074) replication factor C (activator 1) 1
52 SM2588 d5 Rps27l 21.58 1.06 0.660 (+0.087) ribosomal protein S27-like
53 SM2169 b7 Slc25a14 21.96 1.07 0.630 (+0.039) solute carrier family 25member 14
54 SM2558 f9 Stfa3 21.99 0.97 0.717 (+0.104) stefin A3
55 SM2591 c7 Taf7l 21.64 0.99 0.659 (+0.101) TAF7-like RNA polymerase II, TBP-associated factor
56 SM2573 d3 Tbx18 22.25 1.07 0.733 (+0.184) T-box18
57 SM2181 e5 Tcf20 21.94 1.11 0.613 (+0.114) transcription factor 20
58 SM2175 d6 Tmem179b 22.57 1.10 0.334 (+0.055) transmembrane protein 179B
59 SM2591 c1 Tmem25 21.61 1.11 0.620 (+0.099) transmembrane protein 25
60 SM2141 e9 Trappc9 21.62 0.95 0.778 (+0.149) trafficking protein particle complex 9
61 SM2587 g7 Tspan10 22.22 1.09 0.514 (+0.035) tetraspanin 10
62 SM2149 a4 Txlna 21.78 1.06 0.579 (+0.021) taxilin alpha
63 SM2579 c2 Wdr37 21.92 1.06 0.764 (+0.122) WD repeat domain 37
List of 63 shRNAs suppressing Nhtt150Q-EGFP aggregation without distinct alteration of Nhtt16Q-EGFP expression in neuro2a cells. Targets genes of shRNAs and data
summary of 1st (z-score), 2nd (ratio to control) and 3rd screening (ratio to control 6 SD) are described. In case of Pik3c2a, two different shRNAs were obtained. Clone IDs
of shRNAs are originally named in this paper based on plate number and well position of the shRNA.
doi:10.1371/journal.pone.0093891.t001
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1st (150Q) 2nd (16Q) 3rd (150Q)
No Clone ID Gene z-score Ratio Ratio (+ SD) Gene Description
1 SM2592 c7 Aimp2 2.24 1.13 1.446 (+0.331) ARS interacting multifunctional protein 2
2 SM2023 a1 Aldh3b1 2.98 1.04 1.270 (+0.158) aldehyde dehydrogenase 3 family, member B1
3 SM2598 f6 Arhgap24 1.57 1.05 1.945 (+0.103) Rho GTPase activating protein 24
4 SM2108 a4 C1qtnf9 5.15 1.01 1.246 (+0.311) C1q and tumor necrosis factor related protein 9
5 SM2171 f2 Cish 2.20 1.11 1.717 (+0.647) cytokine inducible SH2-containing protein
6 SM2563 h3 Clec4e 1.86 1.07 1.512 (+0.387) C-type lectin domain family 4, member e
7 SM2566 f12 Cml1 1.71 1.10 1.427 (+0.170) camello-like 1
8 SM2022 g1 Cmpk1 1.89 1.01 1.283 (+0.120) cytidine monophosphate (UMP-CMP) kinase 1
9 SM2179 c5 Cnih2 1.63 0.98 1.905 (+0.244) cornichon homolog 2 (Drosophila)
10 SM2570 c11 Gba 1.88 1.04 1.242 (+0.297) glucosidase, beta, acid
11 SM2110 c2 Gm10336 2.09 1.07 1.439 (+0.055) predicted gene 10336
12 SM2168 g12 Gnai2 2.18 1.07 1.855 (+0.408) G protein alpha inhibiting 2
13 SM2575 d8 Gnpda1 1.74 1.14 1.559 (+0.104) glucosamine-6-phosphate deaminase 1
14 SM2014 g8 Hdac5 3.51 1.02 1.182 (+0.162) histone deacetylase 5
15 SM2598 a11 Krcc1 2.22 1.06 1.340 (+0.225) lysine-rich coiled-coil 1
16 SM2021 a4 Lmln 4.98 0.93 1.398 (+0.218) leishmanolysin-like (metallopeptidase M8 family)
17 SM2111 e11 LOC210191 2.06 1.01 1.476 (+0.136)
18 SM2113 d11 LOC226712 2.83 1.11 1.250 (+0.188)
19 SM2187 d12 Map3k1 1.67 0.98 1.491 (+0.280) mitogen-activated protein kinase kinase kinase 1
20 SM2173 a12 Mark3 1.52 1.15 1.524 (+0.554) MAP/microtubule affinity-regulating kinase 3
21 SM2577 h12 Mei1 1.97 1.15 1.278 (+0.093) meiosis defective 1
22 SM2561 g8 Myl12b 3.45 1.03 1.850 (+0.131) myosin, light chain 12B, regulatory
23 SM2576 e12 Myo19 1.57 1.13 1.345 (+0.124) myosin XIX
24 SM2580 c2 Mypop 1.99 1.10 1.768 (+0.066) Myb-related transcription factor, partner of profilin
25 SM2563 f11 P2rx7 1.60 1.05 1.357 (+0.036) purinergic receptor P2X, ligand-gated ion channel, 7
26 SM2583 c6 Pcdhb18 1.58 1.05 1.776 (+0.165) protocadherin beta 18
27 SM2593 d2 Pcgf3 2.47 1.06 1.307 (+0.198) polycomb group ring finger 3
28 SM2561 h8 Pcp2 2.13 1.00 1.539 (+0.278) Purkinje cell protein 2 (L7)
29 SM2185 f10 Pip5k1b 2.02 1.02 1.423 (+0.324) phosphatidylinositol-4-phosphate 5-kinase, type 1 beta
30 SM2563 h5 Plp2 1.84 1.11 1.652 (+0.352) proteolipid protein 2
31 SM2022 g10 Ptpn11 2.42 1.00 1.292 (+0.176) protein tyrosine phosphatase, non-receptor type 11
32 SM2109 c7 Rassf4 3.49 1.08 1.382 (+0.167) Ras association domain family member 4
33 SM2139 h11 Rnf20 2.06 1.09 1.644 (+0.143) ring finger protein 20
34 SM2109 e10 Serpinb10 3.50 1.04 1.315 (+0.178) serine peptidase inhibitor, clade B, member 10
35 SM2598 h10 Slain2 2.25 0.98 1.479 (+0.284) SLAIN motif family, member 2
36 SM2583 c9 Snx10 1.83 1.10 1.691 (+0.168) sorting nexin 10
37 SM2568 e11 Spa17 1.86 1.09 1.233 (+0.191) sperm autoantigenic protein 17
38 SM2112 g7 Spata21 4.45 0.85 1.523 (+0.099) spermatogenesis associated 21
39 SM2568 h10 St6galnac2 1.65 1.11 1.359 (+0.195) ST6-N-acetylgalactosaminide alpha-2,6-sialyltransferase 2
40 SM2168 f8 Stxbp1 1.52 1.08 1.713 (+0.303) syntaxin binding protein 1
41 SM2568 d8 Sult2a2 1.59 1.11 1.338 (+0.253) sulfotransferase family 2A
42 SM2565 c8 Svep1 2.88 1.08 1.274 (+0.266) sushi, EGF and pentraxin domain containing 1
43 SM2184 a10 Syk 2.91 0.95 1.844 (+0.251) spleen tyrosine kinase
44 SM2559 f11 Syt10 1.74 1.07 1.322 (+0.248) synaptotagmin X
45 SM2142 g10 Tbc1d10c 3.38 1.07 1.402 (+0.046) TBC1 domain family, member 10c
46 SM2587 a10 Tmem63a 1.71 1.05 1.604 (+0.054) transmembrane protein 63a
47 SM2565 b8 Trem1 1.95 1.06 1.419 (+0.125) triggering receptor expressed on myeloid cells 1
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1st (150Q) 2nd (16Q) 3rd (150Q)
No Clone ID Gene z-score Ratio Ratio (+ SD) Gene Description
48 SM2583 e7 Wdpcp 2.38 1.00 1.627 (+0.187) WD repeat containing planar cell polarity effector
List of 48 shRNAs enhancing Nhtt150Q-EGFP aggregation without distinct alteration of Nhtt16Q-EGFP expression in neuro2a cells. Targets genes of shRNAs and data
summary of 1st (z-score), 2nd (ratio to control) and 3rd screening (ratio to control 6 SD) are described. Clone IDs of shRNAs are originally named in this paper based on
plate number and well position of the shRNA.
doi:10.1371/journal.pone.0093891.t002
Figure 4. Classification of the shRNA-target genes. Target genes of the aggregation-suppressing (left chart) or -enhancing (right chart) shRNAs
were classified using PANTHER Classification System based on molecular function (A), PANTHER Protein Class (B), or biological process (C). Genes not
found in the database were classified as unknown. The numbers of classified genes were described.
doi:10.1371/journal.pone.0093891.g004
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library clones and automated cell image analysis using ArrayScan
HCS reader, we identified 111 shRNAs clones that specifically
modified mutant Nhtt aggregation without affecting its expression
in neuro2a cells. The shRNA-target genes were classified into
various cellular functions including transcription and protein
phosphorylation. Subsequent analysis suggests that in addition to
the genes such as Atf3 whose knockdown effect was sensitive to
proteasome inhibition, there were several genes whose knockdown
modified the aggregation independently of it (Figure 10). These
include a transcription factor Tcf20 and kinases Csnk1d and
Pik3c2a. Notably, all the genes except Pik3c2a [33] are not found
by the previous screenings using other organisms such as Drosophila
and C. elegans. Thus, our RNAi screening using mammalian cells
identified novel genes that modify mutant Htt aggregation through
several, possibly mammalian-specific molecular mechanisms.
An identified modifier, Tcf20 (transcription factor 20), contains
several polyQ stretches. Notably, Tcf20, as well as another
relatively Q-rich modifier Hdac5 (histone deacetylase 5), was
found in mutant Htt aggregates by our previous mass spectro-
metric analysis [46]. Indeed, we found co-localization and co-
insolubilization of Tcf20 with mutant Nhtt aggregates through its
N-terminal Q-rich region. In addition, anti-Tcf20 antibody
stained nuclear inclusions of R6/2 mouse brain. Furthermore,
overexpression of Tcf20 also modified the aggregation. These
observations support the idea of physical and probably direct
interaction of Tc20 with mutant Htt aggregates, which modifies
the aggregation. We have previously shown that an RNA binding
protein FUS/TLS, another protein identified by the mass
spectrometry described above, suppresses mutant Htt aggregation
[8]. In contrast, GIT1 (G protein-coupled receptor kinase-
interacting protein), identified by a yeast two-hybrid screen using
mutant Htt as a bait, enhances its aggregation [47]. These
observations suggest that mutant Htt aggregation is differentially
modulated by several interacting proteins, and Tcf20 or Hdac5
may also be the protein that directly modifies it (Figure 10).
Interestingly, the modifiers identified here also include several
aggregation-prone proteins such as Cradd/Raidd [48], Gpr37/
Pael-R [49] and Aimp2/p38 [50]. It would be intriguing to test the
co-aggregation of these with mutant Htt, which could lead to
identification of another potential mechanism of direct modifica-
tion of the mutant Htt aggregation.
We also found several kinases that modify the mutant Htt
aggregation. One of them is Csnk1d (casein kinase 1 delta; CK1d),
a CK1 family kinase that phoshorylates many substrates with
different cellular functions such as cell differentiation, prolifera-
tion, chromosome segregation and circadian rhythm [51].
Pathologically, CK1 is shown to be elevated in Alzheimer patients,
and phosphorylate tau, a protein linked to Alzheimer’s diseases
[51]. Although the role of CK1 in polyQ diseases is unknown,
overexpression of another casein kinase, CK2, is shown to reduce
mutant Htt aggregates possibly through p62-madiated autophagic
clearance [36]. Because we found that Csnk1d knockdown reduces
the aggregates, mutant Htt aggregation may be differentially
modified through these two casein kiasnes, CK1 and CK2
(Figure 10).
Another identified modifier, Pik3c2a (phosphatidylinositol 3
kinase C2 alpha; PI3K-C2a), is a class II PI3K that phosphorylates
39 position of inositol lipids to produce mainly phosphatidylinositol
3-phosphate (PI(3)P) [52,53]. Because Pik3c2a knockdown is also
shown to reduce mutant Htt aggregation in Drosophila,i ti sa n
evolutionally conserved modifier of the aggregation. When
compared with class I conventional PI3K that produces mainly
PI(3,4,5)P3 [52], Pik3c2a has unique structural features, including
a clathrin-binding site in the N-terminal stretch, and relative
resistance to PI3K inhibitors wortmannin and LY294002 [52,54].
Although recent studies suggest its involvement in intracellular
vesicular trafficking and tissue morphogenesis [54–57], the
mechanism by which Pik3c2a modifies mutant Htt aggregation
remains unknown. One potential pathway is through regulation of
RhoA small GTPase, because Pik3c2a knockdown impaired RhoA
activation in endothelial cell [57], and an inhibitor of Rho kinase,
a downstream target of RhoA, suppresses mutant Htt aggregation
in neuro2a cells [58]. In contrast, we found that mutant Htt
aggregation was enhanced by knocking down another PI kinase,
Pip5k1b, which phosphorylates 59 position of inositol lipids to
produce PI(4,5)P2. Increased aggregation of mutant Htt has been
also reported by suppression of a class III PI3K, Vps34, a key
regulator of autophagic clearance of mutant Htt [45]. Thus,
several phosphatidylinositols produced by different PI kinases may
differentially modulate mutant Htt aggregation possibly through
multiple molecular pathways (Figure 10).
Despite the suppression of mutant Nhtt aggregation by knocking
down Tcf20, Csnk1d or Pik3c2a, we could not observe clear
alteration of mutant Nhtt-induced cell toxicity by it. One
possibility is that downregulation of only one gene is insufficient
to alter the toxicity. Indeed, functional and/or physical interaction
with polyglutamine proteins are also reported for several other
shRNA target genes, such as Atf3 [59], Ddx6 [60], Fbxw8 [61],
P2ry1 [62] and Map3k1 [63]. In addition, several shRNA targets
Figure 5. Effect of proteasome or autophagy inhibitor on shRNA-mediated modification of Nhtt150Q-EGFP aggregation. Nhtt150Q-
EGFP cells transfected with control (NSC) or shRNAs for indicated genes were treated with 0.5 mM MG132, 0.5 mM Baf A1 or DMSO together with
ponasterone A for 24 hr. The cells with Nhtt150Q-EGFP aggregates were quantified by ArrayScan reader. Some of shRNA’s suppressive effects on the
aggregation were relieved by treatment with MG132 but not with Baf A1. Values are means 6 SD of four well data (*P,0.05, **P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0093891.g005
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PLOS ONE | www.plosone.org 9 April 2014 | Volume 9 | Issue 4 | e93891Figure 6. Tcf20 interacts with mutant Nhtt aggregates through its N-terminal region in neuro2a cells. (A) Primary sequences of mouse
Tcf20. Glutamine (Q) residues were marked by red. Note that several polyQ stretches are observed in its N-terminal region. (B, C) Neuro2a cells were
transfected with expression vectors for Nhtt150Q-EGFP-NLS (B) or Nhtt150Q-EGFP (C) together with those for indicated V5-tagged proteins. After one
day, the cells were fixed and stained with anti-V5 antibody and Alexa 546-conjugated anti-mouse IgG. Nuclei were stained with DAPI. (B) Tcf20 co-
accumulated with Nhtt150Q-EGFP-NLS aggregate in nucleus whereas it diffusely located in the nucleus without the aggregate. (C) Tcf20 or its N-
terminal fragments accumulated with Nhtt150Q-EGFP aggregates in cytoplasm whereas Rab2b or LacZ did not. (D) Neuro2a cells were co-transfected
with Nhtt150Q-EGFP expression vectors together with those for indicated V5-tagged proteins. After one day, the cells were subjected to Western blot
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polyglutamine disease models, such as Trappc9 [34], Casp3
[64], Gnf1 (Drosophila Rfc1) [65], and F40F8.1 (C. elegans Cmpk1)
[66]. Notably, gene expression array analysis using R6/2 HD
model mice (T.Y and N.N. unpublished data) suggests that some of
the shRNA target genes show altered expression in R6/2 brain
cortex. These include Rab2b (129% to the control, P=0.0016),
Klhl7 (121%, P=0.0050), Fkbp9 (122%, P=0.0098), Plp2
(72.6%, P=0.0023), Mei1 (82.1%, P=0.0208), Pip5k1b (73.6%,
P=4.74E-04) and Rassf4 (80.7%, P=4.58E-04). These observa-
tions suggest potential in vivo significance of these genes for
regulation of mutant polyQ aggregation. Further studies are
needed to understand the molecular mechanisms underlying
regulation of mutant Htt aggregation/toxicity by the modifiers
identified in this study.
In summary, through shRNA screening using neuro2a cells,
here we identified novel mammalian modifiers of mutant Htt
aggregation. Our data suggest that several modifiers mediate their
effect possibly through proteasome-independent mechanism such
as direct interaction with mutant Htt and protein phosphorylation
pathways involving casein kinases and PI kinases. Further studies
focused on our identified modifiers may deepen our understanding
on the molecular mechanism of mutant Htt aggregation and lead
to identification of potential therapeutic targets of HD and other
polyglutamine diseases.
Materials and Methods
Cell lines
Neuro2a mouse neuroblastome cells, a gift from Dr Iwatsubo
(Tokyo University) [35], were maintained in DMEM supplement-
ed with 10% FBS and penicillin-streptomycin in an atmosphere
containing 5% CO2. Stably transfected neuro2a cells, which
inducibly express N-terminal Htt (exon 1) containing 16Q or
150Q fusing EGFP (Nhtt16Q-EGFP or Nhtt150Q-EGFP) under
control of ponasterone A, were cultured as above but the medium
was further supplemented with 0.4 mg/ml of Zeocin and 0.2 mg/
ml of G418 as described previously [35,46]. Note that Zeocin and
G418 were only used for cell maintenance but not for cell
transfection experiments described blow.
Mouse shRNA library
Mouse shRNA libraries (Mouse shRNAmir retroviral library;
release 2.3,2.7 and 2.15) were purchased from Open Biosystems.
In this system, shRNAs, cloned in pSHAG-MAGIC2 (pSM2)
vector, are expressed under U6 promoter as human microRNA-30
(miR30) primary transcripts and efficiently processed by Drosha
and Dicer to produce shRNA. Because the vector contains
puromycin resistant gene, the shRNA-expressing cells were able to
be selected by treatment the cells with puromycin. The shRNA
clones were provided as frozen glycerol stock of E. coli (DH10beta
pir116Frt) in 96 well plates. We first amplified the clones in LB
medium in 96 well culture plates and purified plasmid DNA by
using a plasmid DNA collection system Biomek FX (Beckman
Coulter) accompanied with Wizard MagneSil Tfx system
(Promega). Clones with no or few growth were excluded at this
point. Purities of the clones were estimated by checking their
OD260/280 ratio. At least 4,5 clones in each plate were
randomly picked up and subjected to agarose gel electrophoresis to
check the DNA integrity.
shRNA screening using Nhtt-EGFP cell lines
Stable cells for Nhtt16Q-EGFP or Nhtt150Q-EGFP were
seeded on 96 well plates in 50 ml of culture medium (10% FBS/
DMEM) at density of 2.5610
4 cells per well. On the next day, the
cells were transfected by adding 15 ml Opti-MEM containing
100 ng of shRNA plasmid DNA and 0.2 ml Lipofectamine 2000
(Invitrogen) to the wells. After 5 hr, 50 ml of medium containing
dibutyryl cyclic AMP (dcAMP; final conc. 5 mM) was added to the
well. After overnight incubation, the medium was replaced to one
containing 2.5 mg/ml puromycin and 5 mM dcAMP for selection
of shRNA-expressing cells. After 24 hr incubation, the medium
was replaced to one containing 1 mM of ponasterone A and 5 mM
dcAMP to induce Nhtt-EGFP expression. After 24 hr, cells were
fixed and subjected to nuclear staining with Hoechst or DAPI. The
fluorescence cell images in same area of each well were
automatically obtained and analyzed by ArrayScan HCS Reader
(Cellomics, Thermo Fisher Scientific) along with the protocols
designed by the instruction manual. For data analysis of
Nhtt150Q-EGFP cells, cells with strong EGFP intensities were
counted as aggregate-containing cells because the aggregation
accompanied accumulated EGFP signal in the cells. We then
analysis using anti-V5 and anti-GFP antibodies. Bands for expressed proteins are indicated by arrowheads. Note that gel top bands (indicated by
arrows) were observed for Tcf20 (1,400 or 1,500)-V5 and NF-YA-V5 but not for LacZ-V5 by co-expression of Nhtt150Q-EGFP, suggesting their co-
insolubilization with mutant Nhtt in neuro2a cells. (E) Nhtt150Q-EGFP cells were transfected with expression vectors for Tcf20 (full, 1,400 or 1,500)-
V5 together with pRFP-C1 vector. After one day, cells were treated with ponasterone A for 24 hr and the cells with aggregates in trasnfected (RFP-
positive) cells were quantified by ArrayScan reader. Ratios to control (empty vector) are shown. Values are means 6 SD of four well data (**P,0.01).
Scale bars are 10 mm (B, C).
doi:10.1371/journal.pone.0093891.g006
Figure 7. Anti-Tcf20 antibody stained nuclear inclusions in R6/
2 mouse brain. Coronal brain sections (10 mm thick) of 12-week-old
R6/2 or control male mouse were co-stained with anti-Tcf20 and anti-
Htt (A) or anti-Ub (B). Nuclei were stained with DAPI. Cortical neurons
are shown. Note that nuclear inclusions positive for Htt and Ub were
stained by anti-Tcf20. Scale bars are 20 mm.
doi:10.1371/journal.pone.0093891.g007
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of cells estimated by counting stained nuclei in the same field, and
calculated percentage of cells with aggregates. For data analysis of
Nhtt16Q-EGFP cells, EGFP intensities in each cell were
quantified and averaged by ArrayScan reader. In both analyses,
at least 1000 cells (2000,3000 cells in average) were analyzed for
each well. Scheme of screening procedure is described in Figure 1.
miRNA construction and gene knockdown
Invitrogen miRNAs (miR RNAi) were designed by BLOCK-iT
RNAi Designer in Invitrogen’s Web site. Oligo DNAs used for
miRNA constructions were listed in Table S1. These were cloned
into pcDNA6.2-mRFP-miR vector [36]. By using this vector,
transfected cells expressing miRNA were detected by mRFP
fluorescence. For gene knockdown, Nhtt150Q-EGFP cells seeded
on 24 well plates were transfected with 0.4 mg of miRNA vector by
Lipofectamine 2000 (Invitrogen), according to the manufacturer’s
protocol. After 5 hr of transfection, medium was replaced to one
containing 5 mM dcAMP and cells were further incubated for 2
days. Then, the cells were incubated with 1 mM of ponasterone A
for 24 hr to induce Nhtt150Q-EGFP expression. The cells were
fixed and analyzed by ArrayScan reader and in this case, cells with
Nhtt150Q-EGFP aggregates in RFP-positive, miRNA-transfected
cells were quantified.
Treatment of cells with MG132 or Baf A1
Transfection of Nhtt150Q-EGFP cells with shRNA or miRNA
was performed as described above. MG132 (Chalbochem) or Baf
A1 (LC Laboratories) was co-added to the medium with
ponasterone A. After 24 hr incubation, the cells were fixed and
cells with aggregates were quantified as above.
cDNA expression vectors and cell transfection
The mouse cDNAs for full-length Rab2b (clone ID:
4930528G15) and partial regions of Ddr2 (4732470C17) and
Tcf20 (4930548B22, I830053D05) were kindly provided as
FANTOM3 clones [67]. Remaining regions of Ddr2 and Tcf20
were obtained by RT-PCR to make full-CDS cDNAs. By using
Gateway system, these cDNAs were subcloned into the pcDNA-
DEST40 vector that expresses cDNA product as C-terminal V5-
His tagged protein (Invitrogen). Expression vectors for Tcf20
containing 1,400 or 1,500 amino acid were constructed by
insertion of their fragments amplified by PCR into pcDNA3.1-
V5His vector. Vectors for Nhtt16Q-EGFP, Nhtt150Q-EGFP or
Nhtt150Q-EGFP-NLS in pcDNA3.1 vector (Invitrogen) were
described previously [35,46], and pcDNA3.1-LacZ-V5His vector
was obtained from Invitrogen. To examine the interaction of the
modifiers with mutant Nhtt [12], neuro2a cells were transfected
with above expression vectors by Lipofectamine 2000 (Invitrogen)
and incubated for one day, For immunofluorescence staining, the
cells were fixed with 4% PFA/PBS, permeabilized with 0.1%
triton X-100/TBST (20 mM Tris–HCl, pH 8.0, 150 mM NaCl,
0.05% Tween20), and blocked with 5% goat serum/TBST. The
cells were then incubated with anti-V5 (R960-25, Invitrogen)
diluted with TBST containing 0.1% bovine serum albumin (BSA)
for overnight at 4uC, followed by incubation with Alexa 546-
conjugated anti-mouse IgG (Molecular Probes). The cells were
then mounted in VECTASHIELD with DAPI (VECTOR) and
Figure 8. Kinases whose knockdown modifies Nhtt150Q-EGFP aggregation in neuro2a cells. (A, B) Nhtt150Q-EGFP cells were transfected
with miRNA expression vector. After 2 days, cells were treated with ponasterone A for 24 hr and the cells with aggregates in miRNA trasnfected cells
were quantified by ArrayScan reader. Ratios to control (empty vector) are shown. Note the reproduction of the shRNA’s effect by miRNA binding to
same sequence (OBS) (A) or difference sequences (Inv-1 or -2) (B). (C) Neuro2a cells expressing indicated miRNAs were subjected to quantitative RT-
PCR. (D) Nhtt150Q-EGFP cells expressing indicated miRNAs were treated with 0.5 mM MG132, 0.2 mM Baf A1 or DMSO for 24 hr, and the cells with
aggregates were quantified as above. Ratios to control (empty vector) are shown. Values are means 6 SD of at least three well data (A–C) or six well
data (D) (*P,0.05, **P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0093891.g008
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blot analysis, the cells were boiled in SDS sample buffer and
subjected to Western blotting as described previously [68].
Primary antibodies used were anti-V5 and anti-GFP (04363,
nacalai). Chemiluminescent signals were obtained and quantified
using ImageQuant LAS-4000 (GE). To examine the effect of
Tcf20 overexpression on mutant Nhtt aggregation, Nhtt150Q-
EGFP cells were transfected with expression vectors for Tcf20 (full,
1,400 or 1,500)-V5 together with pRFP-C1 vector. The cells
were then differentiated by dcAMP on the same day and treated
with ponasterone A on the next day. After 24 hr, the cells were
fixed and cells with aggregates in trasnfected (RFP-positive) cells
were quantified by ArrayScan reader.
Immunofluorescence staining of mouse brain sections
The mouse experiments were approved by the animal
experiment committee at RIKEN Brain Science Institute. Mice
were maintained and bred in accordance with RIKEN guidelines.
Heterozygous htt exon 1 transgenic male mice of the R6/2 strain
were obtained from Jackson Laboratory (Bar Harbor, ME) and
maintained as B6CBAF1 background. In this paper, R6/2 male
mice and age-matched littermates were used for experiments. For
immunofluorescence staining [12], frozen raw brains were cut into
10 mm sections. After fixing with 4% PFA/PBS, the sections were
treated with 0.01% H2O2/methanol at room temperature for
30 min and blocked with 5% skim milk/TBST for 1 hr. The
sections were then incubated with a primary antibody diluted with
0.1% BSA/TBST for overnight at 4uC, followed by incubation
with a secondary antibody conjugated with Alexa Fluor dyes
(Molecular Probes). Primary antibodies used were anti-Htt (EM48;
MAB5374, Chemicon), anti-Ub (FK2, BML-PW8810, Enzo) and
anti-Tcf20 (sc-86878, Santa Cruz). The tissues were mounted in
VECTASHIELD with DAPI and analyzed by a Leica confocal
system (TCS SP5).
Figure 9. Effect of knockdown of aggregation-modifiers on
mutant Nhtt-induced cell toxicity. (A) Neuro2a cells were
transfected with siRNAs for NT (non-targeting), Tcf20 (OBS or Inv-1),
Csnk1d (Inv-1) or Pik3c2a (Inv-1). After two days, the cells subjected to
quantitative RT-PCR. Specific and significant reduction of their target
mRNAs was observed. Values are means 6 SD of three well data (*P,
0.05, **P,0.01, *** P,0.001). (B) siRNA-transduced neuro2a cells were
further transfected with expression vector for Nhtt16Q-EGFP or
Nhtt150Q-EGFP. After two days, the cells were co-stained with PI and
Hoechst and subjected to ArrayScan analysis to count PI-positive dead
cells among the cells positive for both Hoechst and GFP. Ratios to
control (NT siRNA- and Nhtt16Q-EGFP-transfected cells) were shown.
Values are means 6 SD of eight well data (***P,0.001).
doi:10.1371/journal.pone.0093891.g009
Figure 10. Scheme of modification of mutant Nhtt aggregation by genes identified by shRNA screening. Our experimental data suggest
that the genes identified here (indicated by red) modify the mutant Nhtt aggregation by several mechanisms. (1) Proteasome-dependent
modification involving Atf3 and Cardd whose knockdown (KD) both suppress the aggregation. (2) Potential direct modification by Q-rich proteins
such as Tcf20 and Hdac5, whose knockdown suppresses or enhances the aggregation, respectively. (3) Casein kinase-mediated modification involving
Csnk1d whose knockdown suppresses the aggregation. In contrast, overexpression (OE) of CK2 is reported to reduce the aggregates by accelerating
p62-dependent autophagic clearance. (4) PI kinase-mediated modification involving Pik3c2a and Pip5k1b, whose knockdown suppresses or enhances
the aggregation, respectively. In contrast, knockdown of Vps34, a class III PI3K, is reported to increase the aggregates by attenuating autophagic
clearance. The S and E indicate suppression and enhancement of the mutant Nhtt aggregation, respectively.
doi:10.1371/journal.pone.0093891.g010
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Preparations of total RNA, reverse transcription and cDNA
synthesis from neuro2a cells were performed as described
previously [6]. We used following primers designed by Primer
Express software (Applied Biosystems) for quantitative PCR;
Csnk1d (GCACGCTATGCCTCCATCA, ACCCCAGA-
GACTCCAAGTCATC), Gapdh
(TGTGTCCGTCGTGGATCTGA, CCTGCTTCAC-
CACCTTCTTGA) and Pik3c2a (TTCATAACCTTGCT-
CAGCTACGTT, GATCCGGCCATCTTGTCTAAAG).
Quantitative PCR was performed by SYBR green according to
the manufacturer’s protocol (Applied Biosystems or Roche). All
values obtained were normalized with respect to levels of Gapdh
mRNA.
siRNA transfection and cell toxicity assay
siRNAs were designed based on miRNA target sequences
(Table S1) and synthesized by Nippon Gene as 39 dTdT
overhangs. The siRNA sequences without overhangs are follows;
no-targeting control (NT) (uagcgacuaaacacaucaa), Tcf20-OBS
(gauaucaagucuauuccua), Tcf20-Inv-1 (ccuauaaguguggcgcuuc),
Csnk1d-Inv-1 (gcuccuucggagacaucua) and Pik3c2a-Inv-1 (uccugc-
guuugacauuauu). These were transduced into cells using RNAi-
MAX (Invitrogen) according to the manufacture’s protocol. After
one day, the cells were transfected with expression vector for
Nhtt16Q-EGFP or Nhtt150Q-EGFP using Lipofectamin 2000
and further incubated for two days in the medium containing
5 mM dcAMP. Then, the cells were co-incubated with 10 mM
pyridinium iodide (PI) and 10 mg/ml Hoechst 33342 for 10 min
and analyzed by ArrayScan reader. Percent of dead cells in Nhtt-
expressing cells was calculated by counting PI-positive cells in the
cells positive for both Hoechst and GFP.
Gene classification
Target genes of final 111 shRNAs were classified using
PANTHER Classification System (http://www.pantherdb.org)
[37]. Ensembl gene IDs (Data S1) were used as inputs for the
analysis. The genes were classified based on their molecular
function, biological process, and PANTHER protein class. We
also performed Statistical Overrepresentation Test for these genes
to examine enrichment of GO term or pathway.
Statistical analysis
For comparison between two sample groups, data were first
analyzed by F-test. For P.0.05, the data were analyzed by
unpaired Student’s t-test (two-tailed); otherwise data were
analyzed by Welch’s t-test (two-tailed). We considered the
difference between comparisons to be significant when P,0.05
for all statistical analyses except of third screening in which
shRNAs with P,0.1 were also included as candidates.
Supporting Information
Data S1 Complete list of the screening data for final 111
shRNAs. Clone IDs, targets genes and data sets of first, second
and third screening for final 111 shRNAs are listed. Clone IDs are
originally named in this paper based on the plate number and well
position of the shRNA. MGI Gene IDs, Ensembl IDs and Entrez
Gene IDs in MGI database, and Oligo IDs, Accessions and
shRNA sequences in supplemented Open Biosystems (OBS)
database are also described.
(XLS)
Data S2 Sequences of cDNAs used for miRNA construc-
tion. cDNA sequences of shRNA target genes used for miRNA
construction. Binding sequences of shRNAs (OBS) are labeled
with blue, whereas those of miRNAs (Inv-1/2) are labeled with
yellow. Coding DNA Sequences (CDS) are underlined. Note that
miRNA-binding sequences are completely different from those of
shRNAs except of Gnpda1 in which partial overlap (labeled with
green) is observed.
(PDF)
Table S1 List of the oligos used for miRNA construc-
tion. OBS means the oligos designed based on Open Biosystems
shRNA sequence. Inv-1/2 means the oligos designed by BLOCK-
iTTM RNAi Designer in Invitrogen’s Web site. Number in
parenthesis indicates starting position of miRNA-target sequence
in coding sequence.
(PDF)
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